| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Other Current Assets
Nektar Therapeutics
Other Current Assets Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Other Current Assets
$10.7m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
6%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Assets
$4.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Assets
$2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Assets
$4.4B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Assets
$7.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Assets
$6.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
See Also
What is Nektar Therapeutics's Other Current Assets?
Other Current Assets
10.7m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Other Current Assets amounts to 10.7m USD.
What is Nektar Therapeutics's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
6%
Over the last year, the Other Current Assets growth was -2%. The average annual Other Current Assets growth rates for Nektar Therapeutics have been -12% over the past three years , -25% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
